Thinking to trade more of Turnstone Biologics (USA Stocks:TSBX)?

Turnstone Biologics Corp (USA Stocks: TSBX) has been making waves in the biotechnology industry, with a recent price percent change of 5.66% and a potential upside of 24.47%. The stock's high price reached $3.6, with a low of $3.18, indicating a strong performance in the market. Despite a Jensen Alpha of -0.43, indicating a loss, the company's mean deviation of 9.66 and variance of 243.13 suggest a high level of volatility, which could be a boon for risk-tolerant investors looking to maximize returns. With a trading volume of 37.8K, it may be time to consider doubling your investment in Turnstone Biologics Corp.

Key Points

Turnstone Biologics Corp has a beta of 8.0768, indicating a relatively significant risk compared to the market. This suggests that if the market rises, the company is likely to outperform it. Conversely, if the market yields negative returns, Turnstone Biologics is expected to underperform. While it's crucial to monitor Turnstone Biologics Corp's current price movements, it's equally important to exercise caution when using historical equity returns. Our approach to predicting any stock's future performance involves examining both its past performance charts and the overall business, including all available technical indicators. Turnstone Biologics Corp provides data on fifteen different technical indicators, which can assist in evaluating its performance. The company has an expected return of -0.42%. It's essential to verify Turnstone Biologics' risk-adjusted performance and information ratio, as well as the relationship between the Information Ratio and kurtosis, to determine if Turnstone Biologics Corp's past performance will be replicated at some point in the near future.
Published over two weeks ago
View all stories for Turnstone Biologics | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Raphi Shpitalnik

Buy low, sell high is the mantra of the stock market. Turnstone Biologics Corp (NASDAQ: TSBX), a prominent player in the Biotechnology industry, is currently undervalued with a market value of $3.36 compared to its real value of $6.74. This discrepancy presents a potential opportunity for investors to maximize returns. The analyst overall consensus indicates a 'Buy' with two strong buys, one hold, and an estimated target price of $17, with the highest and lowest estimates being $20 and $13 respectively. This suggests a significant potential for growth. However, it's important to remember that the stock market is unpredictable and it's crucial to conduct thorough research and consider the hype value of 3.5 before doubling your investment. In the current unique economic climate, Turnstone Biologics Corp may present investors with more surprises in the next two to three weeks. We will explore several reasons why the company still has the potential to generate above-average margins and positive cash flow. Currently, Turnstone Biologics Corp is trading at $3.36. The company has a historical hype elasticity of 0.14, while the average price elasticity to hype among its competitors is approximately 1.25. The firm's value is projected to increase following the next major announcement, with the price expected to rise to $3.5. The current volatility of the media hype's impact on the company's stock price is significantly over 100 percent, making price predictions based on social media less reliable. The price increase following the next news release is projected to be 4.17%, while the daily expected return currently stands at -0.42%. The volatility of related hype on Turnstone Biologics is about 530.28%, with the expected price after the next announcement by a competitor being $4.61. Given an investment horizon of 90 days, the next forecasted press release is expected to be released very soon.
The successful prediction of Turnstone Biologics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Turnstone Biologics Corp, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Turnstone Biologics based on Turnstone Biologics hews, social hype, general headline patterns, and widely used predictive technical indicators. We also calculate exposure to Turnstone Biologics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Turnstone Biologics's related companies.

Use Technical Analysis to project Turnstone expected Price

Turnstone Biologics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Turnstone Biologics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Turnstone Biologics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

Turnstone Biologics Gross Profit

Turnstone Biologics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Turnstone Biologics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Turnstone Biologics Gross Profit growth over the last 10 years. Please check Turnstone Biologics' gross profit and other fundamental indicators for more details.

Breaking down Turnstone Biologics Further

This firm reported the previous year's revenue of 73.3 M. Net Loss for the year was (30.83 M) with profit before overhead, payroll, taxes, and interest of 71.13 M.

Deferred Revenue Breakdown

Turnstone Biologics Deferred Revenue yearly trend continues to be fairly stable with very little volatility. Deferred Revenue is likely to outpace its year average in 2023. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Where this item is not contained on the company consolidated financial statements and cannot otherwise be imputed the value of 0 is used. At this time, Turnstone Biologics' Deferred Revenue is fairly stable as compared to the past year.
201072.4 Million
202219.31 Million
202329.47 Million
"As the saying goes, 'buy low, sell high,' and it seems that now may be the time to double down on your investment in Turnstone Biologics Corp (USA Stocks: TSBX). Despite a high probability of bankruptcy at 96.76%, the company's potential upside of 24.47 and a target price of $17 suggest a significant return on investment. With a market capitalization of 42.94M and gross profit of 71.13M, Turnstone Biologics Corp shows promise. However, investors should be aware of the company's high standard deviation of 15.59, indicating a high level of risk. The company's shares are primarily owned by institutions (34.17%), with insiders owning 8.79%. Despite the risks, the potential rewards may be worth the gamble for those willing to take on a high-risk, high-reward investment strategy."

Turnstone Biologics implied volatility may change after the rise

Turnstone Biologics Corp's stock has recently exhibited significant shifts in its implied volatility, as indicated by the coefficient of variation plunging to -4942.84. This substantial decrease suggests that the stock's volatility is becoming less unpredictable, potentially leading to more consistent trading patterns. However, investors should maintain vigilance as the implied volatility could alter following the recent surge in the stock's value. This could lead to unforeseen price swings, making it essential for investors to closely track Turnstone Biologics' performance in the upcoming weeks. Turnstone Biologics Corp is demonstrating above-average volatility over the chosen time frame. Investors should examine Turnstone Biologics Corp independently to ensure that their intended market timing strategies align with their expectations about Turnstone Biologics' volatility. Understanding different market volatility trends often assists investors in timing the market. Proper utilization of volatility indicators allows traders to gauge Turnstone Biologics' stock risk against market volatility during both bullish and bearish trends. The heightened level of volatility that accompanies bear markets can directly affect Turnstone Biologics' stock price while adding stress to investors as they witness their shares' value decline. This typically compels investors to rebalance their portfolios by purchasing different stocks as prices drop.

The Bottom Line

While other entities in the biotechnology industry are either recovering or due for a correction, Turnstone may not be as strong as the others in terms of longer-term growth potentials. The inconsistency in the assessment between current Turnstone valuation and our trade advice on Turnstone Biologics is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Turnstone Biologics.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Nico Santiago do not own shares of Turnstone Biologics Corp. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to